David Platt insider trades
Open-market stock purchases and sales by David Platt, CEO at Bioxytran, Inc, from SEC Form 4 filings since Mar 20, 2012.
Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -75%.
Recent trades
No open-market trades in the last 12 months.